FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570859902> ?p ?o ?g. }

• W1570859902 endingPage "575" @default.
• W1570859902 startingPage "567" @default.
• W1570859902 abstract "Abstract. Holme I, Fayyad R, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Holdaas H, Pedersen TR, On behalf of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (Centre of Preventive Medicine, Oslo, Norway; Århus University Hospital, Århus, Denmark; Academic Hospital Amsterdam, Amsterdam, The Netherlands; University Hospital, Linköping, Sweden; Helsinki University Central Hospital, Helsinki, Finland; Oslo University Hospital, Rikshospitalet, Oslo, Norway; Pfizer Sweden, Sollentuna, Sweden; and Pfizer Inc., New York, NY, USA). Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: Results from the IDEAL trial. J Intern Med 2010; 267:567–575. Objectives. In Incremental Decrease in Endpoints through Aggressive Lipid-lowering (IDEAL), we compared cardiovascular outcomes in patients with and without chronic kidney disease (CKD) (estimated glomerular filtration rate <60 mL min−1 1.73 m−2) and analysed relationships between lipoprotein components (LC) and major coronary events (MCE) and other cardiovascular (CV) events. Design. Exploratory analysis of CV endpoints in a randomized trial comparing high dose of atorvastatin to usual dose of simvastatin on MCE. Settings. Patients with CKD were compared with the non-CKD patients. Cox regression models were used to study the relationships between on-treatment levels of LC and incident MCE. Findings. Chronic kidney disease was strongly associated with cardiovascular end-points including total mortality. In patients with CKD, a significant benefit of high dose atorvastatin treatment was found for any CV events, stroke and peripheral artery disease, but not for MCE. However, all cardiovascular end-points except stroke and CV mortality were reduced in the non-CKD group. Differential changes in LC or relationships to LC could not explain the different treatment outcomes in MCE in the two groups. Interpretation. Chronic kidney disease was a powerful risk factor for all cardiovascular end-points. The reason why the significant reductions achieved by high-dose statin treatment in most CV end-points in the non-CKD group were only in part matched by similar reductions in the CKD patients is not apparent. This difference did not result from differential changes in or relations to LC, but limited power may have increased the possibility of chance findings." @default.
• W1570859902 created "2016-06-24" @default.
• W1570859902 creator A5011369204 @default.
• W1570859902 creator A5015513489 @default.
• W1570859902 creator A5016704291 @default.
• W1570859902 creator A5019289431 @default.
• W1570859902 creator A5022674575 @default.
• W1570859902 creator A5031764176 @default.
• W1570859902 creator A5032600522 @default.
• W1570859902 creator A5080753043 @default.
• W1570859902 creator A5083340275 @default.
• W1570859902 creator A5088849387 @default.
• W1570859902 date "2009-10-13" @default.
• W1570859902 modified "2023-10-16" @default.
• W1570859902 title "Original Article: Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial" @default.
• W1570859902 cites W1483531931 @default.
• W1570859902 cites W1502524639 @default.
• W1570859902 cites W1922558941 @default.
• W1570859902 cites W1972693268 @default.
• W1570859902 cites W1979397038 @default.
• W1570859902 cites W1983458428 @default.
• W1570859902 cites W1993251788 @default.
• W1570859902 cites W2023154311 @default.
• W1570859902 cites W2055864845 @default.
• W1570859902 cites W2078421357 @default.
• W1570859902 cites W2089151124 @default.
• W1570859902 cites W2100800328 @default.
• W1570859902 cites W2110643382 @default.
• W1570859902 cites W2117848894 @default.
• W1570859902 cites W2122564021 @default.
• W1570859902 cites W2131611175 @default.
• W1570859902 cites W2145632027 @default.
• W1570859902 cites W2146571866 @default.
• W1570859902 cites W2150695109 @default.
• W1570859902 cites W2165141146 @default.
• W1570859902 cites W2562329777 @default.
• W1570859902 cites W40000875 @default.
• W1570859902 cites W4235564602 @default.
• W1570859902 doi "https://doi.org/10.1111/j.1365-2796.2009.02176.x" @default.
• W1570859902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20141566" @default.
• W1570859902 hasPublicationYear "2009" @default.
• W1570859902 type Work @default.
• W1570859902 sameAs 1570859902 @default.
• W1570859902 citedByCount "22" @default.
• W1570859902 countsByYear W15708599022012 @default.
• W1570859902 countsByYear W15708599022013 @default.
• W1570859902 countsByYear W15708599022014 @default.
• W1570859902 countsByYear W15708599022015 @default.
• W1570859902 countsByYear W15708599022016 @default.
• W1570859902 countsByYear W15708599022018 @default.
• W1570859902 countsByYear W15708599022019 @default.
• W1570859902 countsByYear W15708599022020 @default.
• W1570859902 countsByYear W15708599022021 @default.
• W1570859902 countsByYear W15708599022022 @default.
• W1570859902 countsByYear W15708599022023 @default.
• W1570859902 crossrefType "journal-article" @default.
• W1570859902 hasAuthorship W1570859902A5011369204 @default.
• W1570859902 hasAuthorship W1570859902A5015513489 @default.
• W1570859902 hasAuthorship W1570859902A5016704291 @default.
• W1570859902 hasAuthorship W1570859902A5019289431 @default.
• W1570859902 hasAuthorship W1570859902A5022674575 @default.
• W1570859902 hasAuthorship W1570859902A5031764176 @default.
• W1570859902 hasAuthorship W1570859902A5032600522 @default.
• W1570859902 hasAuthorship W1570859902A5080753043 @default.
• W1570859902 hasAuthorship W1570859902A5083340275 @default.
• W1570859902 hasAuthorship W1570859902A5088849387 @default.
• W1570859902 hasConcept C126322002 @default.
• W1570859902 hasConcept C141071460 @default.
• W1570859902 hasConcept C159641895 @default.
• W1570859902 hasConcept C164705383 @default.
• W1570859902 hasConcept C168563851 @default.
• W1570859902 hasConcept C203092338 @default.
• W1570859902 hasConcept C2776329913 @default.
• W1570859902 hasConcept C2776839432 @default.
• W1570859902 hasConcept C2777482532 @default.
• W1570859902 hasConcept C2778213512 @default.
• W1570859902 hasConcept C2778653478 @default.
• W1570859902 hasConcept C50382708 @default.
• W1570859902 hasConcept C71924100 @default.
• W1570859902 hasConceptScore W1570859902C126322002 @default.
• W1570859902 hasConceptScore W1570859902C141071460 @default.
• W1570859902 hasConceptScore W1570859902C159641895 @default.
• W1570859902 hasConceptScore W1570859902C164705383 @default.
• W1570859902 hasConceptScore W1570859902C168563851 @default.
• W1570859902 hasConceptScore W1570859902C203092338 @default.
• W1570859902 hasConceptScore W1570859902C2776329913 @default.
• W1570859902 hasConceptScore W1570859902C2776839432 @default.
• W1570859902 hasConceptScore W1570859902C2777482532 @default.
• W1570859902 hasConceptScore W1570859902C2778213512 @default.
• W1570859902 hasConceptScore W1570859902C2778653478 @default.
• W1570859902 hasConceptScore W1570859902C50382708 @default.
• W1570859902 hasConceptScore W1570859902C71924100 @default.
• W1570859902 hasIssue "6" @default.
• W1570859902 hasLocation W15708599021 @default.
• W1570859902 hasLocation W15708599022 @default.
• W1570859902 hasOpenAccess W1570859902 @default.
• W1570859902 hasPrimaryLocation W15708599021 @default.
• W1570859902 hasRelatedWork W2064446331 @default.

• next